Skip to contentG
Guided Therapeutics Inc
G
GTHPGuided Therapeutics Inc Q3 2021 · 10-Q
Revenue$19.00K$19.00K−75.3% vs Q3 2020 Net Income$68.00K$68.00K−95.7% vs Q3 2020 EPS Diluted$0.00$0.00−100.0% vs Q3 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Guided Therapeutics Inc · CIK 924515 · Engraved from SEC EDGAR
Operating Cash Flowderived-$739,000N/M Free Cash Flowderived-$744,000N/M Margins · derivedGross margin-121.1%−205.5 pt vs Q3 2020
Operating margin-2563.2%−2364.5 pt vs Q3 2020
Net margin357.9%
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end